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ABSTRACT 
 
Objective: The majority of patients with chronic or gestational hypertension do not develop 
pre-eclampsia. Home blood pressure monitoring (HBPM) has the potential to offer a more 
accurate and acceptable means of monitoring hypertensive patients during pregnancy 
compared with traditional pathways of frequent outpatient monitoring. The aim of this study 
was to determine whether HBPM reduces visits to the antenatal services and is safe in 
pregnancy. 
 
Methods: This was a case–control study of non-proteinuric hypertensive pregnant women. 
Patients in the HBPM group were taught how to measure and record their blood pressure 
using a validated machine at home and attended every 1–2 weeks for assessment 
depending on clinical need. The control group was managed as per local protocol. 
 
Results: There were 108 women in the HBPM group and 58 patients in the control group. 
There was no difference in maternal age, parity, body mass index, ethnicity or smoking 
status between the groups, but there were more women with chronic hypertension in the 
HBPM compared with the control group (49.1% vs 25.9%, P=0.004). The HBPM group had 
significantly fewer outpatient attendances (6.5 vs 8.0 visits per patient, P=0.003) and this 
difference persisted when accounting for differences in duration of monitoring (0.8 vs 1.6 
visits per week, p<0.001). There was no difference in the incidence of adverse maternal, 
fetal or neonatal outcomes between the two groups. 
 
Conclusion: Home blood pressure monitoring in hypertensive pregnancies has the potential 
to reduce the number of hospital visits required by patients without compromising maternal 
and pregnancy outcomes. 
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INTRODUCTION 
 
Hypertensive disorders of pregnancy include gestational hypertension, chronic hypertension 
and preeclampsia (PE). They complicate up to 10% of pregnancies and are associated with 
adverse maternal and fetal outcomes such as eclampsia, stroke, renal and hepatic 
dysfunction, fetal growth restriction and stillbirth.3 Monitoring, early recognition, and 
treatment are therefore key to reducing severe complications and mortality.4 Traditionally, 
women who develop hypertension in pregnancy are advised to attend an out-patient service 
or Day Assessment Unit (DAU) at their maternity hospital, commonly two to three times 
weekly for blood pressure monitoring and urine testing.5 The purpose of these assessments 
is to monitor for the development of PE and/or placental insufficiency. However, the vast 
majority of these women (more than 80%) do not develop PE.6 Frequent monitoring can 
represent a source of anxiety to these women and their families, is demanding for them in 
terms of time, transport costs and work absence, and has significant service implications for 
healthcare providers. These women may also undergo unnecessary medical interventions, 
such as early delivery. 
 
An alternative to this pathway is home blood pressure monitoring (HBPM), whereby patients 
monitor and record their own blood pressure using a validated machine with instructions 
from a healthcare professional on the frequency of monitoring and when to attend the 
hospital. HBPM is recommended in the general population for diagnosing hypertension, but 
there is a paucity of data on the use of HBPM in pregnancy.7-9 It has also been noted that 
30% of pregnant women monitor their own blood pressure without informing their healthcare 
provider and using a wide range of devices, not all of which have been validated in 
pregnancy.10,11 This highlights the need for evidence-based patient education to establish 
and maintain safety of this practice. We therefore developed a pathway for HBPM in 
pregnancy where eligible women performed the majority of the blood pressure checks at 
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home and recorded the results on a smartphone application. Our main aim was to assess if 
HBPM can be used in women at risk of PE and whether such monitoring reduces the 
number of hospital appointments without causing discernable adverse outcomes.  
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METHODS 
 
Population and Study Design 
This was a case control study involving a cohort of hypertensive pregnant patients enrolled 
on HBPM pathway and a control group managed according to the traditional pathway of 
regular day assessment unit visits for blood pressure monitoring. The inclusion criteria were 
women with chronic hypertension, GH or women at high risk of developing PE, no significant 
proteinuria (≤1+ protein of urine dipstick testing) and normal biochemical and haematological 
markers. The exclusion criteria were maternal age less than 16 years, systolic blood 
pressure above 155 mmHg or diastolic blood pressure above 100 mmHg, significant 
proteinuria (≥2+ proteinuria on dipstick or protein/creatinine ratio >30mg/mmol), evidence of 
small for gestational age (estimated fetal weight less than 10th centile), signs of severe PE 
(oliguria of less than 500 mL urine output in 24 hours, cerebral or visual disturbance, 
pulmonary oedema, epigastric or right upper quadrant pain, impaired liver function (twice the 
upper limit of normal levels for AST and/or ALT), thrombocytopenia (platelet count less than 
100,000/mm3)), significant mental health concerns and insufficient English language 
understanding. 
 
The diagnosis of PE and gestational hypertension was made according to the criteria of the 
International Society for the Study of Hypertension in Pregnancy.12 In gestational 
hypertension, the systolic blood pressure should be 140 mm Hg or more and/or the diastolic 
blood pressure 90 mmHg or more on at least two occasions four hours apart developing 
after 20 weeks of gestation in previously normotensive women in the absence of significant 
proteinuria. In PE, there should be GH with proteinuria of 300 mg or more in 24 hours, or two 
readings of at least ++ on dipstick analysis of midstream or catheter urine specimens if no 
24-hour collection is available. In PE superimposed on chronic hypertension, significant 
proteinuria (as defined above) should develop after 20 weeks of gestation in women with 
known chronic hypertension (history of hypertension before conception or the presence of 
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hypertension at the booking visit before 20 weeks of gestation in the absence of 
trophoblastic disease). The diagnosis of chronic hypertension was made when there was a 
documented presence of chronic non-gestational hypertension prior to this pregnancy, or 
history of anti-hypertensive medication prior to 20+0 weeks. The diagnosis of White Coat 
Hypertension was made when there were confirmed high blood pressure recordings in the 
hospital/clinic with normal readings on HBPM or ambulatory monitoring.  
 
Patients in the HBPM group presented either via referral to the Hypertension Clinic or to the 
DAU between December 2013 and November 2016. HBPM was implemented as a quality 
improvement initiative at St George’s Hospital. The control group was derived retrospectively 
from maternity databases and consisted of a historic cohort of women who presented to the 
DAU with hypertension in pregnancy and managed as per the local hospital protocol prior 
the implementation of HBPM. Our search criteria included women referred to the DAU for 
blood pressure monitoring who did not have a plan for delivery made within one week of 
their first visit. Ethical approval was obtained for the study (16/NW/0206). 
 
 
Home Blood Pressure Monitoring Pathway 
Eligible patients were counselled and trained by a specialist midwife and provided with an 
automated Microlife© ‘WatchBP Home’ blood pressure machine which has been validated in 
pregnancy and in PE.13 They were taught how to measure their blood pressure accurately 
and record their readings in their notes or on a specially designed smartphone app. Each 
patient was given a personalized schedule of frequency of monitoring and timing of hospital 
visits depending on his or her clinical need. Whilst the schedule varied per patient, the 
frequency of monitoring complied with National Institute for Health and Care Excellence 
(NICE) guidance on hypertension in pregnancy.14 A typical regime for a woman with well-
controlled chronic hypertension would be to measure blood pressure two or three times a 
week whereas a woman initiating new treatment would be asked to measure blood pressure 
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twice a day and reviewed one week later. The same specialist midwife reviewed patients at 
the interim visits and the HBPM recordings were reviewed. Blood pressure and urine were 
assessed and ultrasound for fetal wellbeing was performed as indicated. Patients were given 
written instructions of when to present to hospital based on their home blood pressure 
readings being out of normal range or them reporting symptoms of PE. Our protocol used a 
systolic blood pressure of more than 155mmHg or a diastolic blood pressure of more than 
100mmHg as the trigger for patients to contact the hospital for review to avoid patients 
developing severe hypertension at home. This is in line with the recommendation of hospital 
admission for systolic blood pressure of 160mmHg or diastolic blood pressure of 
110mmHg.14 For those using the smartphone app, a warning was automatically generated if 
they inputted an abnormal reading. Any patients presenting with such concerns were 
reviewed as per normal hospital protocol. Patients in the control group presented either 
directly to the DAU or were referred from an Antenatal Clinic. They were managed according 
to the hospital protocol and had all their blood pressure checks performed in the DAU. The 
hospital protocol at that time was based on National Institute for Health and Care Excellence 
(NICE) guidance on hypertension in pregnancy and follow-up visits were once or twice a 
week depending on blood pressure control.14 
 
Data on maternal age, body mass index (BMI) at booking, ethnicity, parity, smoking, mode of 
conception and pregnancy outcomes were collected. The diagnosis at the start of the blood 
pressure monitoring and at delivery was ascertained from the medical records. We also 
recorded the duration of blood pressure monitoring, number of the blood pressure-related 
visits to the DAU, the Hypertension Clinic, the Family Practitioner practice, number of 
ultrasound scans, hematological and biochemistry tests in the maternal blood, administration 
of steroids, magnesium sulphate, as well as the blood pressure related hospital admissions 
or the need for care on the High Dependency Unit (HDU) admission for severe PE. 
 
 
Page 7 of 22
John Wiley & Sons, Ltd.
Ultrasound in Obstetrics and Gynecology
For Peer Review
 8
Adverse pregnancy outcomes 
The maternity, ultrasound and neonatal records were reviewed to collect data on adverse 
maternal, fetal and neonatal outcomes. Adverse maternal outcomes included acute renal 
failure (maternal serum creatinine level above 100 micromol/L antenatally, or above 130 
postnatally) or need for dialysis, acute myocardial ischaemia, need for third intravenous 
agent to control blood pressure (e.g., in addition to labetalol and hydralazine, hypertensive 
encephalopathy (altered mental status with characteristic cerebral imaging), cortical 
blindness, retinal detachment, stroke (ischaemic or haemorrhagic), pulmonary oedema or 
adult respiratory distress syndrome (defined as characteristic pulmonary imaging in addition 
to oxygen requirement), need for mechanical ventilatory support (other than for Caesarean 
section), disseminated intravascular coagulation, thrombotic thrombocytopenic purpura or 
haemolytic uraemic syndrome, acute fatty liver, liver haematoma or rupture, placental 
abruption and maternal death. Adverse fetal outcomes included preterm delivery (prior to 
37+0 weeks’ gestation), small for gestational age (birthweight below the 10th centile for 
gestational age, fetal growth restriction (birthweight below the 5th centile for gestational age) 
and antepartum or intrapartum fetal death. Adverse neonatal outcomes included neonatal 
death, respiratory distress syndrome, intraventricular haemorrhage, necrotising enterocolitis, 
bronchopulmonary dysplasia, periventricular leukomalacia, retinopathy of prematurity, 
seizure and admission to the neonatal unit for more than 48 hours (for full-term infant). 
 
Statistical Analysis 
The outcome data were obtained from the maternity databases as well as detailed review of 
the patient’s hospital notes. The categorical variables were described as a number and 
percentage and continuous variables as median and interquartile range. The Chi-Square 
test, or Fisher’s exact test when appropriate, was used to compare the categorical variables.  
The Mann Whitney-U test was used for the analysis of the continuous data. A p-value less 
than 0.05 was deemed statistically significant.  All statistical analysis was performed using 
the IBM SPSS Statistics version 24 (IBM Corporation, Armonk, New York, United States).  
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RESULTS 
 
There were 166 women included in the analysis: 29 with HBPM recorded on the smartphone 
app, 79 with HBPM recorded in their medical notes and 58 control patients with conventional 
management. Three women (2.7%) who were approached for HBPM declined, as they were 
not confident in using the technology. Two women (1.8%) initiated on HBPM were 
discontinued at their first review as it became clear they were non-compliant. They reverted 
to the usual care. The demographic characteristics, diagnosis at the beginning of blood 
pressure monitoring and at the end of pregnancy are outlined in Table 1. There were 
significantly more women with chronic hypertension in HBPM compared to the controls 
(49.1% vs 25.9%, p=0.004). Significantly fewer patients developed PE in the HBPM group 
compared to the control group (20.4% vs 34.5%, p= 0.046). Across both groups, 20.6% of 
chronic hypertensives and 32.1% of those with gestational hypertension developed PE.  
 
The duration of outpatient monitoring was significantly longer in the HBPM group (Table 2: 
8.9 vs 4.9 weeks p=0.004). Patients in the HBPM group had significantly fewer visits to the 
DAU (4.0 vs 6.0 visits per patient, p<0.001).  When including other blood pressure-related 
visits to the hypertension clinic, DAU, out-of-hours triage and additional reviews by health 
care staff, the HBPM group had significantly fewer attendances (6.5 vs. 8.0 visits per patient, 
p=0.003). When calculated as the number of visits per week, the HBPM group still had fewer 
visits compared to the control group (0.8 vs 1.6 visits per week, p<0.001). In subgroup 
analysis (Table 3), women with chronic hypertension had significantly fewer visits to the 
DAU and fewer visits per week in the HBPM group than in the control group. Women with 
gestational hypertension also had significantly fewer visits to the DAU compared to controls, 
but no difference in the visits per week. There was no significant difference in the number of 
blood pressure-related hospital admissions in either the group with chronic hypertension or 
gestational hypertension. 
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There were no significant differences in the number of blood pressure-related hospital 
admissions or HDU admissions between the two groups (Table 2). There were also no 
significant differences in adverse outcomes such as gestational age at delivery, birthweight, 
admissions to the neonatal unit, administration of steroids or magnesium sulphate, maternal, 
fetal or neonatal adverse outcomes (Table 4).  
 
 
DISCUSSION 
 
Summary of study findings 
Our results demonstrate that HBPM significantly reduced the number of DAU visits for blood 
pressure monitoring compared to traditional outpatient antenatal monitoring. HBPM was also 
associated with an overall significant reduction in all other antenatal outpatient attendances 
for hypertension-related reasons and this reduction remained significant when accounting for 
differences in the duration of monitoring. The duration of monitoring was significantly longer 
in the HBPM group, which is likely to be due to the greater proportion of patients with chronic 
hypertension who are likely to have started monitoring at an earlier gestational age. There 
were no significant differences in the number of hospital or HDU admissions or any other 
markers of adverse maternal, fetal or neonatal outcomes between the HBPM and control 
groups.  
 
Interpretation of study findings and comparison to the existing literature 
To date, there is limited published literature of HBPM in hypertensive pregnant women. Our 
results demonstrate a reduction in hospital visits for hypertensive pregnant women using 
HBPM without increasing adverse outcomes for either the mother or the baby. Although 
possibly underpowered to assess the adverse maternal, fetal and neonatal outcomes, our 
findings are supported by previous studies of home monitoring in women with gestational 
hypertension.15-17 In their pilot study, Lanssens et al. retrospectively compared antenatal 
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attendances and pregnancy outcomes in 55 hypertensive women using remote monitoring 
with a hypertensive group managed by traditional means. Whilst they reported less hospital 
attendances in the remote monitoring group, this was not significant on multivariate analysis. 
Importantly, their study populations differed with the remote monitoring group having fewer 
preeclamptic women and the study utilized blood pressure monitors that were not validated 
for use in pregnancy. Furthermore, the retrospective nature of the study also increases the 
possibility of selection bias.15 Similarly, Barton et al. compared a large cohort of hypertensive 
pregnant women using home BP monitoring reporting similar maternal and perinatal 
outcomes in this group.1617 Although they also reported fewer days of hospital admission in 
the home BP group, this difference was inevitable as the control group was a historical 
cohort managed as inpatients. The findings were also limited by a non-standardized 
management protocol defined by the patient’s individual private physicians.  
 
Study strengths and limitations 
There were no significant differences in the maternal age, BMI, ethnicity, parity and smoking 
status between the two groups, thereby reducing the risk of confounding for adverse 
outcomes. Our study also benefits from robust data and outcome collection, whereby all 
hospital notes as well as maternity databases were reviewed in order to gain detailed 
information about the number of visits and admissions, as well as the pregnancy outcomes. 
Furthermore, pregnant women in the HBPM group were reviewed by one specialist midwife, 
reducing variation in practice and related biases. 
 
One of the limitations of our study is that the majority of patients in the HBPM group had 
chronic hypertension whereas the control group had significantly more women with 
gestational hypertension. The latter make comparisons between the groups harder to 
interpret as any differences may have been due to the management of the underlying 
condition rather than HBPM itself. However, our subgroup analysis demonstrated that there 
was still a significant reduction in DAU and total outpatient visits in the patients with chronic 
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hypertension on HBPM and a significant reduction in DAU visits in the GH group on HBPM. 
Secondly, the control group was recruited retrospectively meaning selection bias cannot be 
excluded. Finally, our HBPM protocol was designed to comply with the organization and 
recommended practice of antenatal care in the United Kingdom which may not be 
representative of antenatal care in other countries. This should be considered when applying 
the results to other populations. 
 
Clinical and research implications 
Despite the paucity of evidence regarding the use of HBPM in pregnancy many professional 
bodies acknowledge the potential benefits and need for further research.8,18,19 This is one of 
the first studies to compare HBPM with traditional monitoring in a hypertensive pregnant 
population. The finding of a reduction in hospital visits for hypertension-related reasons 
without an increase in maternal or fetal harm support the notion that a large randomized trial 
is justified. If women developed PE whilst on HBPM, they reverted to the traditional care 
pathway. Therefore, our findings cannot be applied to a PE population and the role of HBPM 
in PE remains unclear. Concerns over differences in the home and clinic readings of PE 
patients using an automated device and mercury sphygmomanometry have been reported,20 
and although validation studies for devices used in pregnancy often include PE patients, 
readings in this group may be less accurate.11,21,22 
 
Our study was not designed to compare the ability of HBPM with traditional monitoring in 
detecting PE and this is an important question to be addressed in any future trials. 
Ambulatory blood pressure monitoring (ABPM) in pregnancy has been shown to be effective 
in diagnosing white coat hypertension and therefore reducing unnecessary intervention and 
HBPM is likely to offer a similar benefit.23,24 Conversely, it would be hoped that HBPM would 
allow for earlier detection of severe hypertension and PE by virtue of the patients measuring 
their blood pressure more frequently than if they were attending traditional outpatient 
monitoring. The fact that significantly fewer patients in the HBPM group progressed to PE 
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may be explained by the fact that HBPM, as compared to conventional care, offers a closer follow 
up in women at risk for PE, allowing for better fine tuning of antihypertensive therapy with subsequent 
lower risk for progression to a more advanced and severe stage of the disease, but the difference 
was small and should be interpreted with caution in view of the differences in the underlying 
diagnoses. ABPM studies have shown higher 24-hour readings in patients who 
subsequently develop PE or fetal growth restriction when compared to routine BP 
measurements, however refinement is required in enabling these measures to be used as a 
prognostic tool.23-27 
 
HBPM is acceptable to patients and does not appear to increase anxiety.28,29 It requires less 
visits to hospital which can save both time and money for patients. Many patients self-
monitor their BP in pregnancy without the advice of a healthcare professional and using a 
large variety of devices.10,11 It is therefore important to develop evidence-based protocols to 
ensure this practice is performed safely. Finally, HBPM has the potential to offer cost 
savings and service improvements by reducing the number of lengthy visits required. This is 
important in both low and high-income settings which are all under strain to streamline 
services. 
 
CONCLUSION 
Our results suggest that using HBPM in hypertensive pregnancies has the potential to 
reduce the number of hospital visits required by patients without compromising safety. A 
larger prospective study is now warranted to further explore whether HBPM can make a 
difference in terms of requirement of antihypertensive treatment, requirement of early 
delivery for blood pressure-related reasons, maternal and fetal adverse outcomes.  
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Table 1. Description of the two study groups.  
 
 Home Blood 
Pressure group 
(n=108) 
Control group 
(n=58) 
P 
Maternal age (years) 32.5 (21-54) 32 (16-44) 0.185 
Body mass index (Kg/m2) 27.7 (17.9-55.2) 27.9 (20.1-44.2) 0.986 
Ethnicity 
  Caucasian 
  Afro-Caribbean 
  Asian 
  Mixed/Other 
 
69 (63.9) 
20 (18.5) 
16 (14.8) 
3 (2.8) 
 
38 (65.5) 
13 (22.4) 
7 (12.1) 
0 (0) 
 
0.834 
0.549 
0.625 
0.200 
Nulliparous 61 (56.5) 32 (55.2) 0.871 
Smokers 3 (2.8) 1 (1.7) 0.673 
Assisted Conception 6 (5.6) 1 (1.7) 0.242 
Starting Diagnosis 
  Chronic Hypertension 
  Gestational Hypertension 
  Previous history of preeclampsia 
  White Coat Hypertension 
 
53 (49.1) 
47 (43.5) 
6 (5.6) 
2 (1.9) 
 
15 (25.9) 
37 (63.8) 
4 (6.9) 
2 (3.4) 
 
0.004 
0.013 
0.729 
0.522 
End Diagnosis 
  Chronic Hypertension 
  Gestational Hypertension 
  Preeclampsia 
  Normotensive 
  White Coat Hypertension 
 
43 (39.8) 
33 (30.6) 
22 (20.4) 
8 (7.4) 
2 (1.9) 
 
11 (19) 
25 (43.1) 
20 (34.5) 
2 (3.4) 
0 (0) 
 
0.006 
0.106 
0.046 
0.307 
0.543 
 
Values are given as median (interquartile range) or n (%).Comparisons between the two 
study groups by X2 test and Fisher’s exact test for categorical variables and Mann–Whitney 
test for continuous variables 
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Table 2. Antenatal outpatient visits and hospital admissions per patient in the group 
undertaking Home Blood Pressure Monitoring and the control pregnancies.  
 
 
 Home Blood Pressure 
group 
(n=108) 
Control group 
(n=58) 
P 
Duration of monitoring 
(weeks) 
8.9 (0.40-30.6) 4.9 (1.10-18.40) 0.004 
Ultrasound scans for fetal 
assessment 
2 (0-8) 2 (0-5) 0.920 
Blood tests for pre-eclampsia 
 
2 (0-22) 4 (1-32) <0.001 
Number of Day Assessment 
Unit visits 
4 (0-14) 6 (3-18) <0.001 
Number of out-of-hours 
reviews 
0 (0-5) 0 (0-1) 0.384 
Total antenatal outpatient 
attendances for hypertension 
6.5 (0-26) 8.0 (3-31) 0.003 
Total antenatal outpatient 
attendances for hypertension 
per week of monitoring 
0.8 (0-14) 1.6 (0.3-7.9) <0.001 
Total hospital bed stay 
(days) 
4 (1-31) 5 (1-36) 0.200 
High Dependency Unit days 
 
0 (0-7) 0 (0-4) 0.349 
 
Values are given as median (interquartile range). 
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Table 3. Subgroup analysis of the antenatal outpatient visits and hospital admissions per 
patient according to whether the diagnosis at the start of the Home Blood Pressure 
Monitoring (HBPM) was chronic hypertension or gestational hypertension.  
 Chronic hypertension Gestational Hypertension 
 HBPM 
(n=53) 
Control 
(n=15) 
P HBPM 
(n=47) 
Control 
(n=37) 
P 
Number of Day 
Assessment Unit 
visits 
4 (0-11) 7 (3-18) <0.001 4(0-14) 6 (3-16) 0.002 
Total antenatal 
outpatient 
attendances for 
hypertension 
7 (0-26) 11 (4-31) 0.001 5 (1-16) 7 (3-18) 0.33 
Total antenatal 
outpatient 
attendances for 
hypertension per 
week 
0.59 (0-
5.73) 
1.23 
(0.3-2.6) 
0.006 1.23 (0.2-
14) 
1.75 (0.5-
4.1) 
0.191 
Total hospital 
bed stay (days) 
3.5 (1-31) 5 (1-36) 0.189 4 (1-26) 5 (1-14) 0.984 
 
Values are given as median (interquartile range). 
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Table 4. Pregnancy outcomes and adverse maternal, fetal and neonatal events in the two 
study groups.   
 Home Blood Pressure 
group (n=108) 
Control group 
(n= 58) 
P 
Gestational age at birth 
(weeks)  
39 (28.9-41.6) 39.25 (28.3-42.1) 0.395 
Birthweight (gr) 
 
3211 (970-4440) 3100 (450-4700) 0.730 
Neonatal unit admission 
 
12 (11.1) 11 (19) 0.163 
Steroids administration 
 
11 (10.2) 4 (6.9) 0.481 
Magnesium sulphate 
administration 
3 (2.8) 5 (8.6) 0.094 
Adverse maternal outcome* 
 
1 (0.9) 2 (3.4) 0.245 
Adverse fetal outcome† 
 
27 (25) 14 (24.1) 0.902 
Adverse neonatal outcome‡ 
 
6 (5.6) 3 (5.2) 0.979 
Values are given as median (interquartile range) or n (%). 
*Adverse maternal outcomes included acute renal failure (maternal serum creatinine level 
above 100 micromol/L antenatally, or above 130 postnatally) or need for dialysis, acute 
myocardial ischaemia, need for third intravenous agent to control blood pressure (e.g., in 
addition to labetalol and hydralazine, hypertensive encephalopathy (altered mental status 
with characteristic cerebral imaging), cortical blindness, retinal detachment, stroke 
(ischaemic or haemorrhagic), pulmonary oedema or adult respiratory distress syndrome 
(defined as characteristic pulmonary imaging in addition to oxygen requirement), need for 
mechanical ventilatory support (other than for Caesarean section), disseminated 
intravascular coagulation, thrombotic thrombocytopenic purpura or haemolytic uraemic 
syndrome, acute fatty liver, liver haematoma or rupture, placental abruption and maternal 
death. 
  
†Adverse fetal outcomes included preterm delivery (prior to 37+0 weeks’ gestation), small 
for gestational age (birthweight below the 10th centile for gestational age, fetal growth 
restriction (birthweight below the 5th centile for gestational age) and antepartum or 
intrapartum fetal death.  
 
‡Adverse neonatal outcomes included neonatal death, respiratory distress syndrome, 
intraventricular haemorrhage, necrotising enterocolitis, bronchopulmonary dysplasia, 
periventricular leukomalacia, retinopathy of prematurity, seizure and admission to the 
neonatal unit for more than 48 hours (for full-term infant). 
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